Methods of treatment using tlr7 and/or tlr9 inhibitors
AssigneeDynavax Technologies Corporation
InventorsFranck Barrat, Robert L. Coffman, Cristiana Guiducci
Life of this patent
Estimating the term…
Abstract
The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.
Claims36
A method of treating an autoimmune disease in an individual comprising administering to the individual an effective amount of a TLR7 inhibitor and/or TLR9 inhibitor,
- wherein an elevated inflammatory gene expression pattern as compared to that of control sample(s) from healthy subject(s) is present in a sample from the individual at the onset of treatment, and
- wherein the TLR7 and/or TLR9 inhibitor is a polynucleotide comprising the nucleotide sequence of the formula:
- RγJGCKαGIGGLβ-3′ (SEQ ID NO:146), wherein each R, K, and L is a nucleotide, J is U or T, γ is an integer from 0 to 10, α is an integer from 1 to 20, and β is an integer from 1 to 20, and wherein the polynucleotide does not comprise a CG dinucleotide.
7-8. (canceled)
16-17. (canceled)
20-21. (canceled)
A polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:73, SEQ ID NO:134, SEQ ID NO:143 and SEQ ID NO:144.
Dependencies are inferred from the claim text.